The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•1 March 2026•

1 min read

Septerna Reports Positive Phase 1 Data for SEP-631; Phase 2 Trials Set for 2026

Key Facts

1SEP-631 demonstrated robust, dose-dependent inhibition of skin wheal formation, with complete inhibition observed at doses as low as 10 mg once-daily.

Septerna (SEPN) announced successful results from its Phase 1 clinical trial of SEP-631, an oral treatment targeting mast cell-driven diseases. The study demonstrated robust, dose-dependent inhibition of skin wheal formation, with complete inhibition achieved at doses as low as 10 mg once daily. Furthermore, the drug was well-tolerated across all dosage levels, showing a safety profile comparable to the placebo group. These positive findings significantly reduce clinical risk and pave the way for mid-stage development. The company plans to initiate Phase 2 trials for Chronic Spontaneous Urticaria (CSU) in the second half of 2026. This milestone is expected to bolster investor confidence in Septerna's clinical pipeline and overall market valuation.